Acute myeloid leukemia with multilineage dysplasia
MONDO:0019456An acute myeloid leukemia arising de novo and not as a result of treatment. It is characterized by the presence of myelodysplastic features in at least 50% of the cells of at least two hematopoietic cell lines. Patients often present with severe cytopenia.
Also known as: AML with multilineage dysplasia, AML with myelodysplasia-related features, De novo acute myeloid leukaemia with multilineage dysplasia, De novo acute myeloid leukemia with multilineage dysplasia, acute myeloid leukaemia with myelodysplasia-related features, acute myeloid leukemia with myelodysplasia-related features
3123 clinical trials for this condition and its sub-types, 34 tagged with Acute myeloid leukemia with multilineage dysplasia itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
-
New drug combo shows promise for Tough-to-Treat leukemia in younger patients
Disease control CompletedThis study tests a chemotherapy drug called CPX-351 in people under 60 with secondary acute myeloid leukemia (AML), a type of leukemia that develops after other blood disorders or cancer treatments. The goal is to see how well the drug can make the cancer disappear or improve blo…
Phase 2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Can a Platelet-Boosting drug speed recovery for older leukemia patients?
Disease control CompletedThis phase II trial investigates whether eltrombopag, a drug that stimulates platelet production, can help older adults with acute myeloid leukemia (AML) recover their platelet counts faster after initial chemotherapy. Older patients often experience slow platelet recovery, which…
Phase 2 • Sponsor: Case Comprehensive Cancer Center • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New drug cocktail shows promise for tough blood cancers
Disease control CompletedThis study tests a combination of two chemotherapy drugs (CPX-351 and gemtuzumab ozogamicin) in about 50 adults with acute myeloid leukemia (AML) that has returned or not responded to treatment, or with high-risk myelodysplastic syndrome (MDS). The goal is to see if the combo is …
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Could a targeted drug keep AML in check?
Disease control CompletedThis phase III trial tests whether the drug tipifarnib can prevent acute myeloid leukemia (AML) from coming back in patients who are already in remission. Participants include adults over 60 in first remission, those in second or later remission, or those who achieved remission a…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
Could a pill keep AML at bay? new study tests maintenance therapy after chemo
Disease control CompletedThis study looked at whether taking oral azacitidine (Onureg) as maintenance therapy can help older adults with acute myeloid leukemia (AML) stay in remission longer after treatment with CPX-351 chemotherapy. The study included 100 patients aged 65 and older who had achieved remi…
Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New hope for kids with tough leukemia: experimental combo tested
Disease control CompletedThis early-phase study tested a combination of three chemotherapy drugs (CPX-351 and gemtuzumab ozogamicin) in children whose acute myeloid leukemia (AML) had come back or didn't respond to standard treatment. The main goals were to find the best dose and check for side effects. …
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Experimental drug pair targets tough leukemias
Disease control CompletedThis early-phase trial tested a combination of two drugs—veliparib and temozolomide—in 66 adults with relapsed or refractory acute leukemias. Veliparib blocks a DNA repair enzyme, while temozolomide damages cancer cell DNA. The goal was to find the safest dose and check for side …
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Real-World italian study tracks vyxeos Liposomal's impact on Tough-to-Treat AML
Knowledge-focused CompletedThis study observed 113 adults in Italy with acute myeloid leukemia (AML) linked to prior cancer therapy or bone marrow problems. All participants received Vyxeos liposomal as part of their normal care. Researchers tracked how many achieved complete remission without detectable d…
Sponsor: Jazz Pharmaceuticals • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:59 UTC